• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    111, Inc. Announces Second Quarter 2023 Unaudited Financial Results

    8/24/23 2:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $YI alert in real time by email

    SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the second quarter ended June 30, 2023.

    Second Quarter 2023 Highlights

    • Net revenues were RMB3.5 billion (US$479.6 million), representing an increase of 14.5% year-over-year.
    • Gross segment profit(1) increased by 8.3% year-over-year, with B2B segment profit increasing by 11.6% year-over-year.
    • Total operating expenses were RMB249.3million (US$34.4million), compared to RMB271.7 million in the same quarter of last year. As a percentage of net revenues, total operating expenses decreased to 7.2% from 8.9% in the same quarter of last year, which reflected continuous improvement in our operation efficiency.
    • Loss from operations was RMB41.4 million (US$5.7 million), compared to RMB79.8 million in the same quarter of last year. As a percentage of net revenues, loss from operations decreased to 1.2% from 2.6% in the same quarter of last year.
    • Non-GAAP loss from operations(2) was RMB17.2 million (US$2.4 million), compared to RMB52.8 million in the same quarter of last year. As a percentage of net revenues, non-GAAP loss from operations decreased to 0.5% from 1.7% in the same quarter of last year.

    (1) Gross segment profit represents net revenues less cost of goods sold.

    (2) Non-GAAP loss from operations represents loss from operations excluding share-based compensation expenses.

    Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, commented, "We're delighted to announce yet another robust quarter in terms of top-line expansion with narrowed losses both on a GAAP and a Non-GAAP operational basis. Our net revenue saw a rise of 14.5% year-over-year, reaching RMB3.5 billion. This represents the 20th consecutive quarter of year-over-year progression for 111 since our NASDAQ IPO. Additionally, our gross segment profit for this quarter rose by 8.3% compared to the same period last year. Consequently, our operational loss stood at RMB41.4 million (US$5.7 million), down from RMB79.8 million during the same quarter the previous year. When viewed as a percentage of net revenues, the operational loss reduced to 1.2%, compared to 2.6% in the corresponding quarter of the prior year. Meanwhile, Non-GAAP operational loss reduced to RMB17.2 million, dropping to 0.5% of net revenues from the previous 1.7% during the same quarter of the preceding year."

    Mr. Liu added, "Furthermore, we've made strides in improving our operational efficiency, with total operating expenses as a percentage of net revenues falling to 7.2% this quarter, down from 8.9% in the corresponding quarter of the previous year. We anticipate maintaining this positive trajectory as we expand. Concurrently, our dedication remains steadfast in providing top-tier services to our customers and patients."

    "Our recent achievements are a direct result of our unwavering strategic focus, particularly on digitization. In June, we forged a strategic alliance with Tencent to amplify the reach of online pharmaceutical services. By July, 111 secured a spot on the Shanghai Data Exchange, propelling the digital transformation of the pharmaceutical landscape. That same month, we unveiled a pivotal digital supply chain product, bolstering the momentum of supply-side digitization. This quarter, in acknowledgment of 111's digital prowess, the Ministry of Commerce distinguished us as an E-commerce Demonstration Enterprise, placing us among the top 132 nationwide. Capitalizing on our reinforced digital capabilities and robust relationships with over 500 pharmaceutical allies, as well as optimizing operations for 435,000 retail pharmacies, we remain committed to fine-tuning our strategies, and will keep on capitalizing on innovative tools like "Telescope" and tapping into the latest tech advancements, ensuring sustained growth and efficiency.

    "We are confident that our initiatives aimed at margin expansion, cost optimization, and organizational alignment have yielded tangible outcomes. Our focus remains on refining our product selection in line with customer preferences, driving down costs through direct sourcing, and enhancing our market edge with smart pricing strategies. Our commitment to supply chain efficiency and relentless digitization bolsters process enhancement and sparks innovation. With our robust technological prowess, we're poised to scale further, ensure profitability, and consistently amplify value for our shareholders."

    Second Quarter 2023 Financial Results

    Net revenues were RMB3.5 billion (US$479.6 million), representing an increase of 14.5% from RMB3.0 billion in the same quarter of last year.

    (In thousands RMB)

    For the three months ended June 30,



    2022



    2023



    YoY

    B2B Net Revenue











    Product

    2,919,468



    3,367,732



    15.4 %

    Service

    15,155



    20,974



    38.4 %













    Sub-Total

    2,934,623



    3,388,706



    15.5 %













    Cost of Products Sold(3)

    2,765,701



    3,200,156



    15.7 %













    Segment Profit

    168,922



    188,550



    11.6 %

    Segment Profit %

    5.8 %



    5.6 %









    (In thousands RMB)

    For the three months ended June 30,



    2022



    2023



    YoY

    B2C Net Revenue











    Product

    95,879



    83,251



    -13.2 %

    Service

    6,643



    5,540



    -16.6 %













    Sub-Total

    102,522



    88,791



    -13.4 %













    Cost of Products Sold

    79,477



    69,454



    -12.6 %













    Segment Profit

    23,045



    19,337



    -16.1 %

    Segment Profit %

    22.5 %



    21.8 %





    (3) For segment reporting purposes, purchase rebates are allocated to the B2B segment and B2C segments primarily based on the amount of cost of products sold for each segment. Cost of products sold does not include other direct costs related to cost of product sales such as shipping and handling expense, payroll and benefits of logistic staff, logistic centers rental expenses and depreciation expenses, which are recorded in the fulfillment expenses. Cost of service revenue is recorded in the operating expense.

    Operating costs and expenses were RMB3.5 billion (US$485.3 million), representing an increase of 12.9% from RMB3.1 billion in the same quarter of last year.

    • Cost of products sold was RMB3.3 billion (US$450.9 million), representing an increase of 14.9% from RMB2.8 billion in the same quarter of last year. The increase was primarily due to the revenue growth in B2B business, which increased by 15.4% from the same quarter last year.



    • Fulfillment expenses were RMB95.0 million (US$13.1 million), representing an increase of 8.0% from RMB87.9 million in the same quarter of last year. Fulfillment expenses accounted for 2.7% of net revenues this quarter as compared to 2.9% in the same quarter of last year. 



    • Selling and marketing expenses were RMB90.1 million (US$12.4 million), representing a decrease of 10.9% from RMB101.2 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB4.4 million for the quarter and RMB8.4 million for the same quarter last year, respectively, selling and marketing expenses as a percentage of net revenues, accounted for 2.5% in the quarter as compared to 3.1% in the same quarter of last year.



    • General and administrative expenses were RMB39.1 million (US$5.4 million), representing an increase of 1.5% from RMB38.5 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB15.7 million for the quarter and RMB17.0 million for the same quarter last year, respectively, general and administrative expenses as a percentage of net revenues, accounted for 0.7% in the quarter, which  was same as last year.



    • Technology expenses were RMB24.5 million (US$3.4 million), compared with RMB33.7 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB4.2 million for the quarter and RMB1.6 million for the same quarter last year, respectively, technology expenses as a percentage of net revenues, accounted for 0.6% in the quarter as compared to 1.1 % in the same quarter of last year.

    Loss from operations was RMB41.4 million (US$5.7 million), compared to RMB79.8 million in the same quarter of last year. As a percentage of net revenues, loss from operations decreased to 1.2 % in the quarter from 2.6% in the same quarter of last year.

    Non-GAAP loss from operations was RMB17.2 million (US$2.4 million), compared to RMB52.8 million in the same quarter of last year. As a percentage of net revenues, non-GAAP loss from operations decreased to 0.5% in the quarter from 1.7% in the same quarter of last year.

    Net loss was RMB45.4 million (US$6.3 million), compared to RMB84.8 million in the same quarter of last year. As a percentage of net revenues, net loss decreased to 1.3% in the quarter from 2.8% in same quarter of last year.

    Non-GAAP net loss(4) was RMB21.2 million (US$2.9 million), compared to RMB57.8 million in the same quarter of last year. As a percentage of net revenues, non-GAAP net loss decreased to 0.6% in the quarter from 1.9% in same quarter of last year

    Net loss attributable to ordinary shareholders was RMB57.2 million (US$7.9 million), compared to RMB95.3 million in the same quarter of last year. As a percentage of net revenues, net loss attributable to ordinary shareholders decreased to 1.6% in the quarter from 3.1% in same quarter of last year.

    Non-GAAP net loss attributable to ordinary shareholders(5) was RMB33.0 million (US$4.6 million), compared to RMB68.3 million in the same quarter of last year. As a percentage of net revenues, non-GAAP net loss attributable to ordinary shareholders decreased to 0.9% in the quarter from 2.2% in same quarter of last year.

    (4) Non-GAAP net loss represents net loss excluding share-based compensation expenses, net of tax. Considering the impact of accretion of redeemable non-controlling interest for the second quarter 2023, non-GAAP net loss is used as a more meaningful measurement of the operation performance of the Company.

    (5) Non-GAAP net loss attributable to ordinary shareholders represents net loss attributable to ordinary shareholders excluding share-based compensation expenses, net of tax.

    As of June 30, 2023, the Company had cash and cash equivalents, restricted cash and short-term investments of RMB735.8 million (US$101.5 million), compared to RMB922.7 million as of December 31, 2022.

    Conference Call

    111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 24, 2023 (7:30 PM Beijing Time on the same day).

    Details for the conference call are as follows:

    Event Title: 111, Inc. Second Quarter 2023 Unaudited Financial Results

    Registration Link: https://s1.c-conf.com/diamondpass/10032701-ygfhis.html 

    All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.

    Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.

    A telephone replay of the call will be available after the conclusion of the conference call until August 31, 2023 on:

    China: 4001 209 216

    Hong Kong: 800 930 639

    United States: +1 855 883 1031

    International: +61 7 3107 6325

    Conference ID: 10032701

    A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/iw7ck9oc.

    Use of Non-GAAP Financial Measures

    In evaluating the business, the Company considers and uses non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS, as supplemental measures to review and assess its operating performance. The Company defines non-GAAP loss from operations as loss from operations excluding share-based compensation expenses. The Company defines non-GAAP net loss as net loss excluding share-based compensation expenses, net of tax. The Company defines non-GAAP net loss attributable to ordinary shareholders as net loss attributable to ordinary shareholders excluding share-based compensation expenses, net of tax. The Company defines non-GAAP loss per ADS as net loss attributable to ordinary shareholders per ADS excluding share-based compensation expenses, net of tax per ADS. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP.

    The Company believes that non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that it includes in loss from operations and net loss. Share-based compensation expenses is a non-cash expense that varies from period to period. As a result, management excludes the items from its internal operating forecasts and models. Management believes that the adjustments for share-based compensation expenses provide investors with a reasonable basis to measure the company's core operating performance, in a more meaningful comparison with the performance of other companies. The Company believes that non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by the management in their financial and operational decision-making.

    The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, or non-GAAP loss per ADS is that it does not reflect all items of income and expense that affect the Company's operations. Further, the non-GAAP financial measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.

    The Company compensates for these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP measures, all of which should be considered when evaluating the Company's performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure.

    Reconciliation of the non-GAAP financial measures to the most comparable U.S. GAAP measures is included at the end of this press release.

    Exchange Rate Information Statement 

    This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.2513 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of June 30, 2023.

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    About 111, Inc.

    111, Inc. (NASDAQ:YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.

    For more information on 111, please visit: http://ir.111.com.cn/.

    For more information, please contact:

    111, Inc.

    Investor Relations

    Email: [email protected] 

    111, Inc.

    Media Relations

    Email: [email protected]

    Phone: +86-021-2053 6666 (China)

    111, Inc.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except for share and per share data)





    As of

    As of



    December 31, 2022

    June 30, 2023



    RMB





    RMB



    US$

    ASSETS













    Current Assets:













    Cash and cash equivalents

    673,669





    576,414



    79,491

    Restricted cash

    43,122





    36,360



    5,014

    Short-term investments

    205,861





    123,049



    16,969

    Accounts receivable, net

    488,875





    452,003



    62,334

    Notes Receivable

    43,332





    63,934



    8,817

    Inventories

    1,498,900





    1,387,646



    191,365

    Prepayments and other current assets

    282,066





    192,692



    26,574

    Total current assets

    3,235,825





    2,832,098



    390,564

    Property and equipment, net

    48,497





    41,538



    5,728

    Intangible assets, net

    3,267





    2,666



    368

    Long-term investments

    2,000





    2,000



    276

    Other non-current assets

    20,348





    21,435



    2,956

    Operating lease right-of-use asset

    163,877





    150,418



    20,744

    Total Assets

    3,473,814





    3,050,155



    420,636















    LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS'

    DEFICIT













    Current Liabilities:













    Short-term borrowings

    178,990





    309,698



    42,709

    Accounts payable

    1,764,849





    1,512,859



    208,633

    Accrued expense and other current liabilities

    781,271





    498,256



    68,713

    Total Current liabilities

    2,725,110





    2,320,813



    320,055

    Long-term operating lease liabilities

    100,469





    88,638



    12,224

    Total Liabilities

    2,825,579





    2,409,451



    332,279















    MEZZANINE EQUITY













    Redeemable non-controlling interests

    1,056,939





    1,084,753



    149,594















    SHAREHOLDERS' DEFICIT













    Ordinary shares Class A

    31





    32



    5

    Ordinary shares Class B

    25





    25



    3

    Treasury shares

    (40,859)





    (40,859)



    (5,635)

    Additional paid-in capital

    2,977,174





    3,028,583



    417,661

    Accumulated deficit

    (3,426,556)





    (3,515,582)



    (484,821)

    Accumulated other comprehensive income

    75,586





    81,715



    11,269

    Total shareholders' deficit

    (414,599)





    (446,086)



    (61,518)

    Non-controlling interest

    5,895





    2,037



    281

    Total Deficit

    (408,704)





    (444,049)



    (61,237)

    Total liabilities, mezzanine equity and deficit

    3,473,814





    3,050,155



    420,636

     

     

     

    111, Inc.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

    (In thousands, except for share and per share data)





    For the three months ended June 30,



    For the six months ended June 30,



    2022



    2023



    2022



    2023



    RMB



    RMB



    US$



    RMB



    RMB



    US$

    Net Revenues

    3,037,145



    3,477,497



    479,568



    6,019,736



    7,174,258



    989,376

    Operating Costs and expenses:























     Cost of products sold

    (2,845,178)



    (3,269,610)



    (450,900)



    (5,635,234)



    (6,730,158)



    (928,131)

     Fulfillment expenses

    (87,908)



    (94,950)



    (13,094)



    (182,441)



    (197,600)



    (27,250)

     Selling and marketing expenses

    (101,174)



    (90,117)



    (12,428)



    (216,028)



    (179,357)



    (24,734)

     General and administrative expenses

    (38,493)



    (39,079)



    (5,389)



    (86,488)



    (80,396)



    (11,087)

     Technology expenses

    (33,711)



    (24,541)



    (3,384)



    (72,732)



    (49,857)



    (6,876)

     Other operating income, net

    (10,434)



    (605)



    (83)



    (8,718)



    (27)



    (4)

    Total Operating costs and expenses

    (3,116,898)



    (3,518,902)



    (485,278)



    (6,201,641)



    (7,237,395)



    (998,082)

    Loss from operations

    (79,753)



    (41,405)



    (5,710)



    (181,905)



    (63,137)



    (8,706)

     Interest income

    1,421



    2,206



    304



    3,464



    4,155



    573

     Interest expense

    (3,185)



    (4,820)



    (665)



    (6,369)



    (9,092)



    (1,254)

     Foreign exchange loss

    (4,934)



    (2,808)



    (387)



    (4,543)



    (1,174)



    (162)

     Other Income, net

    1,687



    1,450



    200



    3,600



    4,514



    623

    Loss before income taxes

    (84,764)



    (45,377)



    (6,258)



    (185,753)



    (64,734)



    (8,926)

     Income tax expense

    -



    -



    -



    -



    -



    -

    Net Loss

    (84,764)



    (45,377)



    (6,258)



    (185,753)



    (64,734)



    (8,926)

    Net Loss attributable to non-controlling interest

    3,489



    2,122



    293



    7,966



    3,522



    486

    Net Loss attributable to redeemable non-controlling interest

    7,121



    3,728



    514



    16,256



    5,276



    728

    Adjustment attributable to redeemable non-controlling interest

    (21,104)



    (17,712)



    (2,443)



    (44,070)



    (33,090)



    (4,563)

    Net Loss attributable to ordinary shareholders

    (95,258)



    (57,239)



    (7,894)



    (205,601)



    (89,026)



    (12,275)

    Other comprehensive loss























     Unrealized gains of available-for-sale securities,

    1,478



    788



    109



    2,776



    2,923



    403

     Realized gains of available-for-sale debt securities

    (1,128)



    (815)



    (112)



    (2,463)



    (2,717)



    (375)

     Foreign currency translation adjustments

    7,183



    9,037



    1,246



    6,227



    5,924



    817

    Comprehensive loss

    (87,725)



    (48,229)



    (6,651)



    (199,061)



    (82,896)



    (11,430)

    Loss per ADS:























     Basic and diluted

    (1.14)



    (0.68)



    (0.10)



    (2.48)



    (1.06)



    (0.14)

    Weighted average number of shares used in computation of loss per share























     Basic and diluted

    166,595,078



    168,102,392



    168,102,392



    166,463,376



    167,718,135



    167,718,135

     

     

     

    111, Inc.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In thousands)





    For the three months ended June 30,



    For the six months ended June 30,



    2022



    2023



    2022



    2023



    RMB



    RMB



    US$



    RMB



    RMB



    US$

























    Net cash used in operating activities

    (29,935)



    (164,111)



    (22,632)



    (98,176)



    (285,439)



    (39,365)

    Net cash (used in) provided by investing activities

    (52,294)



    139,938



    19,298



    (29,435)



    86,750



    11,964

    Net cash provided by financing activities

    6,394



    15,281



    2,107



    41,672



    93,778



    12,933

    Effect of exchange rate changes on cash and cash equivalents, and restricted cash

    6,695



    2,385



    329



    5,964



    894



    123

    Net decrease in cash and cash equivalents, and restricted cash

    (69,140)



    (6,507)



    (898)



    (79,975)



    (104,017)



    (14,345)

    Cash and cash equivalents, and restricted cash at the beginning of the period

    749,837



    619,281



    85,403



    760,672



    716,791



    98,850

    Cash and cash equivalents, and restricted cash at the end of the period

    680,697



    612,774



    84,505



    680,697



    612,774



    84,505

     

     

     

    111, Inc.

    Unaudited Reconciliation of GAAP and Non-GAAP Results

    (In thousands, except for share and per share data)





    For the three months ended June 30,



    For the six months ended June 30,



    2022



    2023



    2022



    2023



    RMB



    RMB



    US$



    RMB



    RMB



    US$

























    Loss from operations

    (79,753)



    (41,405)



    (5,710)



    (181,905)



    (63,137)



    (8,706)

    Add: Share-based compensation expenses

    26,997



    24,208



    3,338



    56,754



    48,416



    6,677

    Non-GAAP loss from operations

    (52,756)



    (17,197)



    (2,372)



    (125,151)



    (14,721)



    (2,029)

























    Net Loss

    (84,764)



    (45,377)



    (6,258)



    (185,753)



    (64,734)



    (8,926)

    Add: Share-based compensation expenses, net of tax

    26,997



    24,208



    3,338



    56,754



    48,416



    6,677

    Non-GAAP net Loss

    (57,767)



    (21,169)



    (2,920)



    (128,999)



    (16,318)



    (2,249)

























    Net Loss attributable to ordinary shareholders

    (95,258)



    (57,239)



    (7,894)



    (205,601)



    (89,026)



    (12,275)

    Add: Share-based compensation expenses, net of tax

    26,997



    24,208



    3,338



    56,754



    48,416



    6,677

    Non-GAAP net Loss attributable to ordinary shareholders

    (68,261)



    (33,031)



    (4,556)



    (148,847)



    (40,610)



    (5,598)

























    Loss per ADS(6): Basic and diluted

    (1.14)



    (0.68)



    (0.10)



    (2.48)



    (1.06)



    (0.14)

    Add: Share-based compensation expenses per ADS(6), net of tax

    0.32



    0.30



    0.04



    0.68



    0.58



    0.08

    Non-GAAP Loss per ADS(6)

    (0.82)



    (0.38)



    (0.06)



    (1.80)



    (0.48)



    (0.06)



    (6) Every one ADSs represent two Class A ordinary shares.

     

     

    Cision View original content:https://www.prnewswire.com/news-releases/111-inc-announces-second-quarter-2023-unaudited-financial-results-301908866.html

    SOURCE 111, Inc.

    Get the next $YI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on 111, Inc. with a new price target

    Citigroup resumed coverage of 111, Inc. with a rating of Buy and set a new price target of $16.00

    4/15/21 6:56:01 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    SEC Filings

    View All

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    12/17/25 6:13:16 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    9/17/25 6:09:10 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form 20-F/A filed by 111 Inc.

    20-F/A - 111, Inc. (0001738906) (Filer)

    8/29/25 6:03:53 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    111, Inc. Announces Third Quarter 2025 Unaudited Financial Results

    Transition from An Asset-Heavy Business Model to An Asset-Light Business ModelAchieved Quarterly Non-GAAP Net ProfitabilityMaintained Non-GAAP Operational Profitability for Three Consecutive QuartersAchieved Quarterly Positive Operating Cash FlowSHANGHAI, Dec. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Total operating expenses were RMB180.3 million (US$25.3 million)

    12/17/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Second Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoYMaintained Positive Operating Cash Flow in the First Half of the YearSHANGHAI, Sept. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Total operating expenses were RMB185.3 million (US$25.9 million), an improvement of 9.3% compared to RMB204.3 million in

    9/17/25 2:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces First Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoYMaintained Quarterly Positive Operating Cash FlowSHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Net revenues were RMB3.5 billion (US$486.3 million), remaining relatively flat compared to the same quarter last year.Total operating expenses

    6/19/25 3:03:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    2/27/24 8:02:40 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    7/17/23 9:00:05 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    10/31/22 7:57:04 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Financials

    Live finance-specific insights

    View All

    111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results

    Achieved First-Ever Annual Operating ProfitBottom Line Improved by RMB332.7 Million YoY in 2024Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoYAchieved First-Ever Annual Positive Operating Cash FlowSHANGHAI, March 20, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Four

    3/20/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow

    SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2024 ended December 31, 2024, before the U.S. market opens on Thursday, March 20, 2025. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 20, 2025 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Fourth Q

    2/20/25 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Third Quarter 2024 Unaudited Financial Results

    Maintained Operational Profitability for the Third Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoYHeld Positive Operating Cash Flow for Three Consecutive QuartersSHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Net revenues were RMB3.6 billion (US$513.1 million), remaining relatively flat compared to the same

    11/27/24 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Leadership Updates

    Live Leadership Updates

    View All

    111, Inc. Announces Change to Board of Directors

    SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang "Luke" Chen, currently serving as the Company's Senior Finance Executive, as a new director, effective November 4, 2024. Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. "I am grateful to Dr

    11/4/24 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 Announces Appointment of New Auditor

    SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced  the appointment of  Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's boar

    7/19/24 8:45:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, established by the Company's Board of Directors (the "Board") has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding proposal letter dated September 9, 2022 (the "Proposal")

    9/23/22 12:30:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples